HRP20201903T1 - Oligosaharid i postupak za njegovu pripravu - Google Patents
Oligosaharid i postupak za njegovu pripravu Download PDFInfo
- Publication number
- HRP20201903T1 HRP20201903T1 HRP20201903TT HRP20201903T HRP20201903T1 HR P20201903 T1 HRP20201903 T1 HR P20201903T1 HR P20201903T T HRP20201903T T HR P20201903TT HR P20201903 T HRP20201903 T HR P20201903T HR P20201903 T1 HRP20201903 T1 HR P20201903T1
- Authority
- HR
- Croatia
- Prior art keywords
- oligosaccharide
- weight
- less
- daltons
- molecular weight
- Prior art date
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims 21
- 150000002482 oligosaccharides Chemical class 0.000 title claims 21
- 238000000034 method Methods 0.000 title claims 10
- 238000002360 preparation method Methods 0.000 title claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 4
- 125000003172 aldehyde group Chemical group 0.000 claims 3
- 238000000746 purification Methods 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Oligosaharid koji ima težinu prosječnu molekulsku težinu (Mw) od manje od 3000 daltona, naznačen time, da navedeni oligosaharid sadrži funkcionalne aldehidne skupine i ima udio dimernog saharida od 2,9 % težinskih ili manje, na osnovu ukupne težine oligosaharida.
2. Oligosaharid prema patentnom zahtjevu 1, naznačen time, da je udio monomernog saharida 0,5 % težinskih ili manje, na osnovu ukupne težine oligosaharida.
3. Oligosaharid prema patentnom zahtjevu 1 ili 2, naznačen time, da udovoljava Europskoj farmakopeji, stavka 01/2009:1506.
4. Oligosaharid prema bilo kojem patentnom zahtjevu 1 do 3, naznačen time, da je težina prosječna molekulska težina (Mw) oligosaharida 850 do 1150 daltona.
5. Oligosaharid prema bilo kojem patentnom zahtjevu 1 do 4, naznačen time, da je hidrogenirani oligosaharid.
6. Postupak za pripravu oligosaharida prema bilo kojem patentnom zahtjevu 1 do 5, naznačen time, da postupak obuhvaća korake:
(a) hidroliziranje polisaharida kako bi se reducirala njegova molekulska težina, gdje nastali oligosaharid sadrži funkcionalne aldehidne skupine, i
(b) frakcioniranje oligosaharida prema molekulskoj težini, tako da pročišćena frakcija ima težinu prosječnu molekulsku težinu jednaku ili manju od 3000 daltona,
gdje korak (b) obuhvaća postupak pročišćavanja jednim ili više membranskih postupaka s graničnim vrijednostima između 340 i 800 daltona, a koji se postupak nastavlja sve dok se udio dimernog saharida u pročišćenoj frakciji oligosaharida ne reducira do 2,9 % težinskih ili manje, na osnovu ukupne težine oligosaharida.
7. Postupak prema patentnom zahtjevu 6, naznačen time, da se navedeno pročišćavanje nastavlja sve dok se udio monomernog saharida u pročišćenoj frakciji ne reducira do 0,5 % težinskih ili manje, na osnovu ukupne težine oligosaharida.
8. Postupak prema patentnom zahtjevu 6 ili 7, naznačen time, da nadalje obuhvaća korak
(c) hidrogeniranje frakcioniranog oligosaharida kako bi se funkcionalne aldehidne skupine konvertirale u alkoholne skupine.
9. Postupak prema bilo kojem od patentnih zahtjeva 6 do 8, naznačen time, da oligosaharid udovoljava Europskoj farmakopeji, stavka 01/2009:1506.
10. Postupak prema bilo kojem od patentnih zahtjeva 6 do 9, naznačen time, da je težina prosječna molekulska težina (Mw) oligosaharida 850 do 1150 daltona.
11. Oligosaharid, naznačen time, da ga se može dobiti postupkom prema patentnim zahtjevima 6 do 10.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16201189.4A EP3156075B1 (en) | 2009-03-25 | 2009-03-25 | An oligosaccharide and a process for preparation thereof |
| PCT/DK2009/050069 WO2010108493A1 (en) | 2009-03-25 | 2009-03-25 | A stable iron oligosaccharide compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201903T1 true HRP20201903T1 (hr) | 2021-01-22 |
Family
ID=41350678
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170230TT HRP20170230T1 (hr) | 2009-03-25 | 2017-02-13 | Stabilan spoj željezo oligosaharida |
| HRP20201903TT HRP20201903T1 (hr) | 2009-03-25 | 2020-11-30 | Oligosaharid i postupak za njegovu pripravu |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170230TT HRP20170230T1 (hr) | 2009-03-25 | 2017-02-13 | Stabilan spoj željezo oligosaharida |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US8815301B2 (hr) |
| EP (3) | EP3821910A1 (hr) |
| JP (1) | JP5426010B2 (hr) |
| KR (1) | KR101580348B1 (hr) |
| CN (3) | CN109700828A (hr) |
| AU (1) | AU2009342799B2 (hr) |
| BR (1) | BRPI0924653B8 (hr) |
| CA (1) | CA2756580A1 (hr) |
| CY (2) | CY1118725T1 (hr) |
| DK (2) | DK3156075T3 (hr) |
| EA (1) | EA023917B1 (hr) |
| ES (2) | ES2840074T3 (hr) |
| HK (1) | HK1164138A1 (hr) |
| HR (2) | HRP20170230T1 (hr) |
| HU (2) | HUE030866T2 (hr) |
| LT (2) | LT3156075T (hr) |
| MX (1) | MX2011009936A (hr) |
| NZ (1) | NZ595597A (hr) |
| PH (1) | PH12015500891B1 (hr) |
| PL (2) | PL2411053T3 (hr) |
| PT (2) | PT3156075T (hr) |
| RS (2) | RS55700B1 (hr) |
| SI (2) | SI2411053T1 (hr) |
| UA (1) | UA103373C2 (hr) |
| WO (1) | WO2010108493A1 (hr) |
| ZA (1) | ZA201107431B (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1973549B1 (en) | 2006-01-06 | 2016-07-20 | Luitpold Pharmaceuticals, Inc. | Methods and compositions for administration of iron |
| BRPI0924653B8 (pt) | 2009-03-25 | 2021-05-25 | Pharmacosmos Holding As | composto de ferro-oligossacarídeo, composição e uso de deste composto |
| CN103626807B (zh) * | 2013-11-20 | 2017-07-07 | 青岛国风药业股份有限公司 | 一种多糖铁复合物的制备方法及其质量检测方法 |
| CZ2014451A3 (cs) * | 2014-06-30 | 2016-01-13 | Contipro Pharma A.S. | Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití |
| PT3212182T (pt) * | 2014-10-27 | 2019-07-29 | Pharmacosmos Holding As | Tratamento ou prevenção da anemia em mamíferos não humanos em período de gestação e ninhada |
| EP3310364B1 (en) * | 2015-06-22 | 2021-09-15 | Pharmacosmos Holding A/s | Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant |
| CA2932075C (en) * | 2015-09-01 | 2020-11-17 | Particle Dynamics International, Llc | Iron-polysaccharide complexes and methods for the preparation thereof |
| US10258647B2 (en) | 2015-09-01 | 2019-04-16 | Particle Dynamics International, Llc | Iron-polysaccharide complexes and methods for the preparation thereof |
| CN105908611A (zh) * | 2016-06-12 | 2016-08-31 | 天津康远工程机械有限公司 | 具有清洗功能的自动找平双层预应力烫平板 |
| EP3450443A1 (en) | 2017-08-29 | 2019-03-06 | Jennewein Biotechnologie GmbH | Process for purifying sialylated oligosaccharides |
| BR112020004357A2 (pt) * | 2017-09-11 | 2020-09-08 | Pharmacosmos Holding A/S | compostos de complexo de ferro para uso terapêutico |
| CN109646454A (zh) * | 2018-12-29 | 2019-04-19 | 博瑞生物医药（苏州）股份有限公司 | 异麦芽糖酐铁1000的制备方法 |
| SG11202107050RA (en) | 2019-01-10 | 2021-07-29 | Pharmacosmos Holding As | Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation |
| EA202191858A1 (ru) | 2019-06-12 | 2021-11-12 | Фармакосмос Холдинг А/С | Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий |
| US11447513B2 (en) * | 2020-02-12 | 2022-09-20 | Rk Pharma Inc. | Purification process of ferric carboxymaltose |
| CN118019542A (zh) | 2021-08-03 | 2024-05-10 | 法码科思莫斯控股有限公司 | 用于在治疗伴侣动物缺铁中皮下使用的铁络合化合物 |
| WO2024069644A1 (en) * | 2022-09-30 | 2024-04-04 | West Bengal Chemical Industries Limited | A pharmaceutically acceptable ferric carboxymaltose and preparation thereof |
| CN116726045B (zh) * | 2023-06-30 | 2024-03-19 | 重庆汉佩生物科技有限公司 | 一种氟雷拉纳组合物 |
| CN116672360B (zh) * | 2023-06-30 | 2024-05-14 | 重庆汉佩生物科技有限公司 | 一种妥曲珠利与葡庚糖酐铁的组合物 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA623412A (en) | 1961-07-04 | Muller Arthur | Iron polyisomaltose complexes for therapeutical application | |
| CA623411A (en) | 1961-07-04 | Muller Arthur | Process for the manufacture of iron-polyisomaltose complex for therapeutical purposes | |
| US2807610A (en) * | 1952-02-15 | 1957-09-24 | Baker Chem Co J T | Hydrogenated dextran |
| US3100202A (en) | 1960-06-17 | 1963-08-06 | Muller Arthur | Process for preparing an iron hydroxide polyisomaltose complex and the resulting product |
| US3076798A (en) | 1961-02-23 | 1963-02-05 | Hausmann Lab Ltd | Process for preparing a ferric hydroxide polymaltose complex |
| DE1293144B (de) | 1964-11-04 | 1969-04-24 | Hausmann Ag Labor | Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid |
| US3639588A (en) | 1966-10-22 | 1972-02-01 | Fisons Pharmaceuticals Ltd | Pharmaceutical compositions containing ferric hydroxide complexed with dextran or dextrin heptonic acids |
| GB1594697A (en) * | 1977-04-19 | 1981-08-05 | Pharmacia Ab | Oligosaccharide compositions for parenteral use |
| DE3026868C2 (de) | 1980-07-16 | 1986-03-13 | Laboratorien Hausmann AG, St. Gallen | Verfahren zur Herstellung von Eisen(III)hydroxid-Dextran-Komplexen und sie enthaltende pharmazeutische sterile wäßrige Lösung |
| US4518581A (en) * | 1981-11-02 | 1985-05-21 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Imparting low- or anti-cariogenic property to orally-usable products |
| DE3422249A1 (de) | 1984-06-15 | 1985-12-19 | Pfeifer & Langen, 5000 Köln | Wasserloesliches eisendextran und verfahren zu seiner herstellung |
| US5624668A (en) | 1995-09-29 | 1997-04-29 | Luitpold Pharmaceuticals, Inc. | Iron dextran formulations |
| US6219440B1 (en) | 1997-01-17 | 2001-04-17 | The University Of Connecticut | Method and apparatus for modeling cellular structure and function |
| DK172860B1 (da) | 1998-03-25 | 1999-08-16 | Pharmacosmos Holding As | Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman |
| DK173138B1 (da) * | 1998-11-20 | 2000-02-07 | Pharmacosmos Holding As | Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma |
| US7871597B2 (en) | 1999-04-09 | 2011-01-18 | Amag Pharmaceuticals, Inc. | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
| WO2000061191A2 (en) | 1999-04-09 | 2000-10-19 | Advanced Magnetics, Inc. | Heat stable coated colloidal iron oxides |
| KR20020096284A (ko) * | 2001-06-19 | 2002-12-31 | 현대자동차주식회사 | 자동차의 연료 누유 진단장치 |
| DE60307249T2 (de) | 2002-04-09 | 2007-03-15 | Pharmacosmos Holding A/S | Eisen-dextrin verbindung zur behandlung von anämien durch eisenmangel |
| DE10249552A1 (de) | 2002-10-23 | 2004-05-13 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
| US6960571B2 (en) | 2003-03-14 | 2005-11-01 | Luitpold Pharmaceuticals, Inc. | Methods and compositions for administration of iron for the treatment of restless leg syndrome |
| US20060116349A1 (en) | 2003-03-14 | 2006-06-01 | Luitpold Pharmaceuticals, Inc. | Methods and compositions for administration of iron for the treatment of restless leg syndrome |
| US7964568B2 (en) * | 2003-05-30 | 2011-06-21 | Chromaceutical Advanced Technologies, Inc. | Synthesis of high molecular weight iron-saccharidic complexes |
| PT1848446E (pt) | 2005-02-09 | 2009-12-21 | Vifor Int Ag | Uso de complexos de ferro (iii) |
| ITMO20050056A1 (it) | 2005-03-15 | 2006-09-16 | Biofer Spa | Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi. |
| CN100528237C (zh) * | 2005-04-26 | 2009-08-19 | 重庆医药工业研究院有限责任公司 | 多核的氢氧化铁-糖复合物的制备方法 |
| EP1757299A1 (de) | 2005-08-25 | 2007-02-28 | Vifor (International) Ag | Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung |
| EP1973549B1 (en) | 2006-01-06 | 2016-07-20 | Luitpold Pharmaceuticals, Inc. | Methods and compositions for administration of iron |
| EP1997833A1 (de) | 2007-05-29 | 2008-12-03 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydratderivat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
| BRPI0924653B8 (pt) | 2009-03-25 | 2021-05-25 | Pharmacosmos Holding As | composto de ferro-oligossacarídeo, composição e uso de deste composto |
| US20150202224A1 (en) | 2012-07-27 | 2015-07-23 | Luitpold Pharmaceuticals, Inc. | Method of treating iron deficiency anemia |
| US20140121193A1 (en) | 2012-11-01 | 2014-05-01 | Robert S. Katz | Methods for treating fibromyalgia |
| WO2014083169A1 (en) | 2012-11-30 | 2014-06-05 | Pharmacosmos A/S | Cryoprotecting agent, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation |
-
2009
- 2009-03-25 BR BRPI0924653A patent/BRPI0924653B8/pt active IP Right Grant
- 2009-03-25 CN CN201810296939.5A patent/CN109700828A/zh active Pending
- 2009-03-25 CN CN201810292732.0A patent/CN108752395A/zh active Pending
- 2009-03-25 HU HUE09776213A patent/HUE030866T2/en unknown
- 2009-03-25 PT PT162011894T patent/PT3156075T/pt unknown
- 2009-03-25 SI SI200931621A patent/SI2411053T1/sl unknown
- 2009-03-25 LT LTEP16201189.4T patent/LT3156075T/lt unknown
- 2009-03-25 EA EA201190214A patent/EA023917B1/ru not_active IP Right Cessation
- 2009-03-25 DK DK16201189.4T patent/DK3156075T3/da active
- 2009-03-25 KR KR1020117025035A patent/KR101580348B1/ko active IP Right Grant
- 2009-03-25 SI SI200932104T patent/SI3156075T1/sl unknown
- 2009-03-25 WO PCT/DK2009/050069 patent/WO2010108493A1/en active Application Filing
- 2009-03-25 ES ES16201189T patent/ES2840074T3/es active Active
- 2009-03-25 LT LTEP09776213.2T patent/LT2411053T/lt unknown
- 2009-03-25 PT PT97762132T patent/PT2411053T/pt unknown
- 2009-03-25 JP JP2012501133A patent/JP5426010B2/ja active Active
- 2009-03-25 EP EP20200455.2A patent/EP3821910A1/en active Pending
- 2009-03-25 MX MX2011009936A patent/MX2011009936A/es active IP Right Grant
- 2009-03-25 RS RS20170157A patent/RS55700B1/sr unknown
- 2009-03-25 CN CN2009801582967A patent/CN102361651A/zh active Pending
- 2009-03-25 UA UAA201111767A patent/UA103373C2/ru unknown
- 2009-03-25 NZ NZ595597A patent/NZ595597A/xx unknown
- 2009-03-25 CA CA2756580A patent/CA2756580A1/en not_active Abandoned
- 2009-03-25 HU HUE16201189A patent/HUE052617T2/hu unknown
- 2009-03-25 EP EP16201189.4A patent/EP3156075B1/en active Active
- 2009-03-25 EP EP09776213.2A patent/EP2411053B1/en active Active
- 2009-03-25 US US13/138,669 patent/US8815301B2/en active Active
- 2009-03-25 PL PL09776213T patent/PL2411053T3/pl unknown
- 2009-03-25 AU AU2009342799A patent/AU2009342799B2/en active Active
- 2009-03-25 DK DK09776213.2T patent/DK2411053T3/en active
- 2009-03-25 PL PL16201189T patent/PL3156075T3/pl unknown
- 2009-03-25 RS RS20201417A patent/RS61104B1/sr unknown
- 2009-03-25 ES ES09776213.2T patent/ES2617658T3/es active Active
-
2011
- 2011-10-11 ZA ZA2011/07431A patent/ZA201107431B/en unknown
-
2012
- 2012-05-18 HK HK12104882.9A patent/HK1164138A1/zh unknown
-
2014
- 2014-06-18 US US14/307,957 patent/US9439969B2/en active Active
- 2014-06-18 US US14/308,198 patent/US20140364598A1/en not_active Abandoned
-
2015
- 2015-04-21 PH PH12015500891A patent/PH12015500891B1/en unknown
-
2016
- 2016-07-28 US US15/222,306 patent/US10865255B2/en active Active
-
2017
- 2017-02-13 HR HRP20170230TT patent/HRP20170230T1/hr unknown
- 2017-02-20 CY CY20171100226T patent/CY1118725T1/el unknown
-
2018
- 2018-11-02 US US16/178,943 patent/US10414831B2/en active Active
-
2020
- 2020-10-29 US US17/083,366 patent/US20210108004A1/en active Pending
- 2020-11-30 HR HRP20201903TT patent/HRP20201903T1/hr unknown
- 2020-12-23 CY CY20201101214T patent/CY1123651T1/el unknown
-
2021
- 2021-01-06 US US17/142,442 patent/US11851504B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201903T1 (hr) | Oligosaharid i postupak za njegovu pripravu | |
| Wang et al. | Overview on biological activities and molecular characteristics of sulfated polysaccharides from marine green algae in recent years | |
| Dong et al. | Structural characterization and immunostimulating activity of a levan-type fructan from Curcuma kwangsiensis | |
| HRP20220500T1 (hr) | Pripravci i postupci za glikoziliranje proteina | |
| Lee et al. | Anti-influenza A virus effects of fructan from Welsh onion (Allium fistulosum L.) | |
| Hamman | Composition and applications of Aloe vera leaf gel | |
| Mancilla-Margalli et al. | Water-soluble carbohydrates and fructan structure patterns from Agave and Dasylirion species | |
| WO2008144514A3 (en) | Polyol-based polymers | |
| Zou et al. | Characterization and bioactivity of polysaccharides obtained from pine cones of Pinus koraiensis by graded ethanol precipitation | |
| Wang et al. | Insight into polysaccharides from Panax ginseng CA Meyer in improving intestinal inflammation: modulating intestinal microbiota and autophagy | |
| Zhang et al. | Extract methods, molecular characteristics, and bioactivities of polysaccharide from alfalfa (Medicago sativa L.) | |
| MX2007004047A (es) | Goma de caramelo que comprende chocolate. | |
| WO2008142036A3 (en) | Plant cells and plants with increased tolerance and/or resistance to environmental stress and increased biomass production-ko | |
| MX2015005786A (es) | Formulacion de accion rapida de insulina que comprende un compuesto anionico sustituido. | |
| Rodrigues et al. | Anticoagulant activity of a sulfated polysaccharide isolated from the green seaweed Caulerpa cupressoides | |
| NO20050508L (no) | Polysakkarid fra Echinacea angustifolia | |
| Qu et al. | Potential of myricetin to restore the immune balance in dextran sulfate sodium-induced acute murine ulcerative colitis | |
| CN103880975A (zh) | 一种岩藻聚糖硫酸酯及其制备方法和在制备抗流感病毒药物中的应用 | |
| Li et al. | Characterization of low molecular weight sulfate ulva polysaccharide and its protective effect against IBD in mice | |
| Bahramzadeh et al. | An arabinogalactan isolated from Boswellia carterii: Purification, structural elucidation and macrophage stimulation via NF-κB and MAPK pathways | |
| AR084583A1 (es) | Sistemas de polimeros | |
| JP2009057481A5 (hr) | ||
| de Britto et al. | Effect of carboxymethylcellulose and plasticizer concentration on wetting and mechanical properties of cashew tree gum–based films | |
| CN102191298A (zh) | 一种高效降解果胶多糖的方法 | |
| Chen et al. | Hypoglycemic polysaccharides from the tuberous root of Liriope spicata |